Incyte registers Phase 2 trial of INCA33890 in MRD-positive colorectal cancerSep 16Trial updateINCA33890Incyte Corporation
Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance studySep 11Weekly roundup, 2 itemsadagrasibBristol Myers Squibb
Incyte registers Phase 3 MAESTRA 3 trial in cyclin E1-overexpressing ovarian cancerSep 1Trial updateINCB123667Incyte Corporation
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PGAug 24Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Incyte posts results for Phase 1/2 anti-PD-1, LAG-3, TIM-3 combo trial in advanced malignanciesAug 17Trial updateINCAGN02385INCAGN02390
Incyte-linked filings this week: FIGHT-302 results posted, new academic pancreatic trial listedAug 14Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Incyte raises 2026 sales guidance, adds ten data readouts, closes Vega dealJul 28Quarterly updateIncyte Corporation
Trial registered for tafasitamab plus rituximab in newly diagnosed follicular lymphomaJul 28Trial updateIncyte Corporationrituximab
Lilly posts SURPASS-CVOT results; tirzepatide compared to dulaglutide on cardiovascular eventsJul 10Weekly roundup, 8 itemsAstraZenecabaricitinib
Incyte-linked ruxolitinib trials post results; both MGH and UT Southwestern studies reportJul 9Weekly roundup, 2 itemsIncyte Corporationruxolitinib
Sign in